Palliative and end-of-life care for patients with ovarian cancer

Clinical Obstetrics and Gynecology

Volumn 55, Issue 1, 2012, Pages 173-184

  Radwany, Steven M ^a   Von Gruenigen, Vivian E ^b  

^a SUMMA HEALTH SYSTEM   (United States)

^b AKRON CITY HOSPITAL   (United States)

Author keywords

end of life care; ovarian cancer; palliative care

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; AMIFOSTINE; ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CAPSAICIN; CARBAMAZEPINE; CITALOPRAM; CORTICOSTEROID; GABAPENTIN; GLUTAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; LIDOCAINE; LOPERAMIDE; MORPHINE; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; OCTREOTIDE; OPIATE; PARACETAMOL; PREGABALIN; RADIOPHARMACEUTICAL AGENT; TRAMADOL; VALPROIC ACID; VENLAFAXINE;

ADJUVANT THERAPY; ANTICHOLINERGIC EFFECT; ANXIETY; ARTICLE; ASCITES; BONE PAIN; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; COMPREHENSION; CONSTIPATION; DECISION MAKING; DEPRESSION; DIARRHEA; DISEASE COURSE; DYING; EDEMA; FAMILY; FATIGUE; HUMAN; HYPERCALCEMIA; INTERPERSONAL COMMUNICATION; MUCOSA INFLAMMATION; MUSCULOSKELETAL PAIN; NAUSEA AND VOMITING; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; OVARY CANCER; PERIPHERAL NEUROPATHY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; SOCIAL ASPECT; SPIRITUAL CARE; SYMPTOM; TERMINAL CARE; TRUST; URINARY TRACT DISEASE;

ANTINEOPLASTIC AGENTS; ANXIETY; ASCITES; BEREAVEMENT; COMMUNICATION; CONSTIPATION; DECISION MAKING; DEPRESSION; DYSPNEA; FATIGUE; FEMALE; HOSPICES; HUMANS; HYPERCALCEMIA; INTESTINAL OBSTRUCTION; LYMPHEDEMA; MUCOSITIS; NAUSEA; OVARIAN NEOPLASMS; PAIN MANAGEMENT; PALLIATIVE CARE; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSICIAN'S ROLE; PHYSICIAN-PATIENT RELATIONS; PROFESSIONAL-FAMILY RELATIONS; PROGNOSIS; QUALITY OF LIFE; URETERAL OBSTRUCTION; VOMITING;

EID: 84857566200     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e31824b1af1     Document Type: Article

References (25)

1. http://www.who.int/cancer/palliative. Accessed September 10, 2010.
2. Muir JC, Daly F, Davis MS, et al. Integrating palliative care into the outpatient, private practice oncology setting. J Pain Symptom Manage. 2010;40:126-135.
3. Mularski RA, Dy SM, Shugarman LR, et al. A systematic review of measures of end-of-life care and its outcomes. Health Serv Res. 2007;42:1848-1870. (Pubitemid 47397188)
4. von Gruenigen VE, Daly BJ. Futility: clinical decisions at the end-of-life in women with ovarian cancer. Gynecol Oncol. 2005;97:638-644. (Pubitemid 40614915)
5. Buckman RH. How to Break Bad News: A Guide for Health Care Professionals. Baltimore: Johns Hopkins Press; 1992.
6. von Gruenigen V, Daly B, Gibbons H, et al. Indicators of survival duration in ovarian cancer and implications for aggressiveness of care. Cancer. 2008;112: 2221-2227. (Pubitemid 351628632)
7. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733-742.
8. Caraceni A, Portenoy RKThe IASP Task Force on Cancer Painan international survey of cancer pain characteristics and syndromes. Pain. 1999;82:263-274. (Pubitemid 29369094)
9. Wood GJ, Shega JW, Lynch B, et al. Management of intractable nausea and vomiting in patients at the end of life. JAMA. 2007;298:1196-1207.
10. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008; 358:2482-2494.
11. www.nccn.org. Accessed June 1, 2011.
12. Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2007;4:CD000978.
13. Clarkson JE, Worthington HV, Furness S, et al. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2010;8:CD001973.
14. Hamilton CA, Maxwell GL, Chernofsky MR, et al. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol. 2008;111:530-532.
15. Antony VB, Loddenkemper R, Astoul P, et al. Management of malignant pleural effusions: official statement of the American Thoracic Society. Am J Respir Crit Care Med. 2000;162:1987-2001.
16. Akl EA, Barba M, Rohilla S, et al. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2008;6:CD006650.
17. Cella D, Peterman A, Passik S, et al. Progress toward guidelines for the management of fatigue. Oncology. 1998;12: 369-377.
18. Minton O, Richardson A, Sharpe M, et al. Drug therapy for the management of cancer-related fatigue. Cochrane Database of Syst Rev. 2010;7:CD006704.
19. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacologic management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85:S3-S14.
20. Santarpia L, Koch CA, Sarlis NJ. Hypercalcemia in cancer patients: pathobiology and management. HormMetab Res. 2010; 42:153-164.
21. Block SD, for the ACP-ASIM End of- Life Care Consensus. Panelassessing and managing depression in terminally ill patients. Ann Intern Med. 2000;132: 209-218. (Pubitemid 30064921)
22. Earle CC, Neville BA, Landrum MB, et al. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004;22:315-321. (Pubitemid 41095097)
23. Wee B, Hillier R. Interventions for noisy breathing in patients near to death. Cochrane Database Syst Rev. 2008;1: CD005177.
24. Cherny NI, Radbruch L, for the EAPC Board European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. Palliat Med. 2009;23:581-593.
25. Brown D, Roberts JA, Elkins TE, et al. Hard choices: the gynecologic cancer patient's end-of-life preferences. Gynecol Oncol. 1994;55:355-362.